| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJM198601233140404 |
| P698 | PubMed publication ID | 3001523 |
| P2093 | author name string | J D Meyers | |
| D H Shepp | |||
| P S Dandliker | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | aciclovir | Q147101 |
| P304 | page(s) | 208-212 | |
| P577 | publication date | 1986-01-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Treatment of varicella-zoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidarabine | |
| P478 | volume | 314 |
| Q40720231 | "The end of innocence" revisited: resistance of herpesviruses to antiviral drugs |
| Q72006536 | A Case of Herpes Zoster Myelitis Occurring During Epidural Analgesia |
| Q90748060 | A fatal case of severe systemic varicella zoster infection in a patient with chronic use of immunosuppressive agents for cutaneous vasculitis |
| Q43567469 | A randomized, double-blind trial of famciclovir versus acyclovir for the treatment of localized dermatomal herpes zoster in immunocompromised patients |
| Q37809492 | Aciclovir and Varicella-zoster-immunoglobulin in solid-organ transplant recipients |
| Q34291342 | Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy |
| Q28353263 | Acyclovir for treatment of postherpetic neuralgia: efficacy and pharmacokinetics |
| Q34500573 | Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy |
| Q35186637 | Acyclovir: A Decade Later |
| Q38202572 | Advances in the management of viral infections |
| Q73571845 | Alteration in the radiation-induced LD release in HeLa cells by acyclovir |
| Q67514516 | Antiviral agents |
| Q68833359 | Antiviral agents |
| Q40433521 | Antiviral agents in dermatology: current status and future prospects |
| Q34152399 | Antiviral lead compounds from marine sponges |
| Q45835136 | Antiviral sensitivities of the acute retinal necrosis syndrome virus |
| Q39465086 | Antiviral therapy |
| Q41142734 | Antiviral therapy of acute herpes zoster in older patients |
| Q43669773 | Antiviral therapy. New drugs and their uses |
| Q36070394 | Antiviral therapy: current concepts and practices |
| Q45781449 | Attenuated varicella virus vaccine in children with renal transplants |
| Q36156348 | Bone marrow transplantation and the lung |
| Q37939570 | Choice of antibiotics, pharmacokinetics, and dose adjustments in acute and chronic renal failure. |
| Q34358014 | Clinical practice: Herpes zoster |
| Q41201529 | Clinically significant drug interactions with cyclosporin. An update |
| Q42277527 | Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus |
| Q33585362 | Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment |
| Q37559627 | Cytomegalovirus and varicella-zoster virus vaccines in hematopoietic stem cell transplantation |
| Q37426542 | Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation |
| Q40058091 | Diagnostics and management of herpes zoster ophthalmicus |
| Q45843624 | Disseminated ecthymatous herpes varicella-zoster virus infection in patients with acquired immunodeficiency syndrome |
| Q74182998 | Effect of acyclovir on the radiation-induced micronuclei and cell death |
| Q38942259 | European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. |
| Q36721283 | Herpes zoster and its neurological complications |
| Q39758708 | Herpes zoster and the immunocompromised |
| Q37901418 | Herpesvirus and enteric viral infections in bone marrow transplantation: clinical presentations, pathogenesis, and therapeutic strategies |
| Q39217722 | Herpesvirus infections in pregnancy: risks to embryo, fetus, and neonate. |
| Q74106533 | High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients |
| Q36721365 | Human immunodeficiency virus (HIV) infection for the general physician |
| Q39643357 | Human infection with herpes zoster: etiology, pathophysiology, diagnosis, clinical course, and treatment |
| Q45095772 | Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group |
| Q44701041 | Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual triad in a patient 6 months post mini-allogeneic peripheral stem cell transplant for chronic myeloid leukemia |
| Q38006193 | Infections caused by herpes viruses other than cytomegalovirus in solid organ transplant recipients. |
| Q39523011 | Infectious complications in childhood acute leukemias. |
| Q28360556 | Inhibiting effect of (RS)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine on varicella-zoster virus replication in cell culture |
| Q41557335 | Late infections following allogeneic bone marrow transplantation: suggested strategies for prophylaxis |
| Q35849423 | Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study |
| Q43796854 | Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation |
| Q59349149 | Long-term study showed that vaccination protected paediatric renal transplant recipients from life-threatening varicella zoster virus |
| Q33852014 | Management of HIV-infected children in the home and institutional settings. Care of children and infections control in schools, day care, hospital settings, home, foster care, and adoption |
| Q43547992 | Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia |
| Q34104608 | Measuring quality of life in clinical trials: a taxonomy and review |
| Q37612093 | Neurologic manifestations of varicella zoster virus infections |
| Q37199848 | New Antiviral Drugs for Treatment of Viral Infections in Immunocompromised Patients |
| Q34074994 | Novel agents for the therapy of varicella-zoster virus infections |
| Q37925989 | Ocular problems in AIDS. |
| Q30493410 | Oncology |
| Q37671247 | Optimal management of acute toxicities of therapy |
| Q37263293 | Pathogenesis and current approaches to control of varicella-zoster virus infections |
| Q35121549 | Pharmacokinetics and safety of multiple-dose valaciclovir in geriatric volunteers with and without concomitant diuretic therapy. |
| Q36753818 | Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients |
| Q37901455 | Pneumonias in adults due to mycoplasma, chlamydiae, and viruses |
| Q69370386 | Postherpetic neuralgia |
| Q41421708 | Postherpetic neuralgia: a review |
| Q67967421 | Prenatal toxicity of acyclovir in rats |
| Q28360591 | Pyrrolo[2,3-d]pyrimidine nucleosides as inhibitors of human cytomegalovirus |
| Q45271669 | Quality of life as outcome measures in randomized clinical trials. An overview of three general medical journals |
| Q40395708 | Recognition and treatment of shingles |
| Q40784610 | Recombinant interferon alpha-2a for treatment of herpes zoster in immunosuppressed patients with cancer |
| Q28315869 | Recommendations for the Management of Herpes Zoster |
| Q42282265 | Reversible renal failure in renal transplant patients receiving oral acyclovir prophylaxis |
| Q38379825 | Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies. |
| Q33645952 | Severe herpes zoster ophthalmicus in young African adults: a marker for HTLV-III seropositivity |
| Q47682483 | Short-course intravenous aciclovir treatment for cutaneous herpes zoster in patients with HIV infection |
| Q40774513 | Special considerations for the patient undergoing allogeneic or autologous bone marrow transplantation. |
| Q36442845 | The child with cancer and infection. II. Nonbacterial infections |
| Q39563538 | The future of antiviral chemotherapy |
| Q35978431 | Tolerability of treatments for postherpetic neuralgia |
| Q68055156 | Unusual onset of severe varicella in adult immunocompromised patients |
| Q72348548 | Use of irradiated lymphocytes from immune donors for treatment of disseminated varicella |
| Q37153278 | Use of murine monoclonal antibodies for laboratory diagnosis of varicella-zoster virus infection |
| Q40278402 | Varicella |
| Q45776638 | Varicella in children with perinatally acquired human immunodeficiency virus infection |
| Q34615689 | Varicella zoster virus (VZV) in solid organ transplant recipients. |
| Q42272322 | Varicella zoster virus in solid organ transplantation |
| Q45863343 | Varicella-Zoster Virus Retinitis in Patients With the Acquired Immunodeficiency Syndrome |
| Q39188767 | Varicella-zoster virus infection and immunization in the healthy and the immunocompromised host |
| Q34527694 | Varicella-zoster virus: atypical presentations and unusual complications |
| Q45755341 | Varicella-zoster virus: infection, control, and prevention |
| Q40722959 | Viral infections in leukemia and bone marrow transplant patients |
| Q40594928 | Viral infections in severely immunocompromised cancer patients |
| Q69852467 | Viral infections in the acquired immunodeficiency syndrome |
| Q69810065 | [Is the administration of immunoglobulins following bone marrow transplantation indicated?] |
| Q81093064 | [Pain therapy in herpes zoster and post-zoster neuralgia.]. |
| Q94563514 | [S2k guideline for the diagnosis and therapy of zoster and post-zoster neuralgia] |
Search more.